Business
Aileron Therapeutics Provides Business Update and Outlines 2022 Strategic Priorities to Deliver Key Milestones
Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22Planned readouts for ongoing
About this update from Rein Therapeutics, Inc.
[{"type":"text","content":"Plans to initiate Phase 1b clinical trial of ALRN-6924 in neoadjuvant breast cancer in 1H22; interim results expected in 4Q22Planned readouts for ongoing randomized, double-blind, placebo-controlled non-small cell lung cancer (NSCLC) trial on track for interim results in 2Q22 and topline results in 4Q22 Dosed first 10 patients in NSCLC trial; on track to conduct blinded safety evaluation on these patients after one cycle in 1Q22 In 2021, Aileron was issued 7 new international patents, including new patent protection for ALRN-6924 in China, and 4 U.S. patents, adding to its strong intellectual property portfolio comprising over 170 U.S. and foreign patents and exclusive worldwide rights to ALRN-6924 BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN), a chemoprotection oncology company that aspires to develop medicines to make chemotherapy safer and thereby more effective to save more patients’ lives, today provided a business update and outlined the company’s strategic priorities for 2022. “All cancer patients undergoing chemotherapy – still the standard of care for most patients – experience chemotherapeutic side effects to varying degrees, from unpleasant to fatal. Utilizing a biomarker strategy, we are developing ALRN-6924 as a selective chemoprotective agent to shift the paradigm from accepting these side effects to preventing them for patients with p53-mutated cancer regardless of type of cancer or chemotherapy,” said Manuel Aivado, M.D., Ph.D., President and Chief Executive Officer at Aileron. “In 2022, we expect several key milestones may propel us toward this vision, including our planned initiation of a clinical trial in breast cancer patients receiving neoadjuvant chemotherapy in the first half of the year with interim results in the fourth quarter, as well as planned interim and topline data readouts for our ongoing NSCLC trial in the second and fourth quarters, respectively.” Aileron is developing ALRN-6924 to selectively protect healthy cells in patients with p53-mutated cancers to reduce or eliminate chemotherapy-induced side effects. Nearly 1 million patients each year are diagnosed with a p53-mutated cancer in the US alone, and Aileron employs a precision medicine approach to exclusively treat those patients with p53-mutated cancers who are receiving chemotherapy. ALRN-6924 is designed to...